11 November 2026

Individualising tildrakizumab Treatment to Optimise Psoriasis Outcomes

9 minute read

Growing real-world evidence, alongside maintenance dose flexibility, further reinforces tildrakizumab's role within the IL-23 class.

This content is for AHPRA registered professionals only.
Login Join Now

End of content

No more pages to load

Email Address

Password

Confirm Password

First Name

Last Name

Full Name LEAVE THIS BLANK

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

I agree to the Terms and conditions and privacy policy *

Processing...